Regentatlantic Capital LLC Has $2,721,000 Stake in Celgene Corporation (CELG)
Regentatlantic Capital LLC held its position in shares of Celgene Corporation (NASDAQ:CELG) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,950 shares of the biopharmaceutical company’s stock at the end of the second quarter. Regentatlantic Capital LLC’s holdings in Celgene Corporation were worth $2,721,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in the stock. State Street Corp raised its position in shares of Celgene Corporation by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after buying an additional 723,844 shares during the period. Bank of New York Mellon Corp raised its position in shares of Celgene Corporation by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock valued at $1,255,309,000 after buying an additional 472,067 shares during the period. American Century Companies Inc. raised its position in shares of Celgene Corporation by 4.4% in the first quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock valued at $816,733,000 after buying an additional 276,089 shares during the period. Pioneer Investment Management Inc. raised its position in shares of Celgene Corporation by 15.7% in the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after buying an additional 710,584 shares during the period. Finally, Clearbridge Investments LLC raised its position in shares of Celgene Corporation by 24.1% in the first quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock valued at $572,617,000 after buying an additional 892,392 shares during the period. 79.43% of the stock is owned by institutional investors and hedge funds.
Celgene Corporation (NASDAQ:CELG) traded up 1.70% on Monday, hitting $131.89. The stock had a trading volume of 1,271,819 shares. The firm has a market cap of $103.18 billion, a price-to-earnings ratio of 40.85 and a beta of 1.89. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $139.00. The company’s 50 day moving average price is $133.39 and its 200 day moving average price is $125.39.
Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business’s revenue was up 18.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.44 EPS. Analysts expect that Celgene Corporation will post $7.32 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/regentatlantic-capital-llc-has-2721000-stake-in-celgene-corporation-celg/1528246.html.
Several equities analysts have weighed in on CELG shares. BTIG Research lowered Celgene Corporation from a “buy” rating to a “neutral” rating and increased their price objective for the company from $96.93 to $131.70 in a report on Friday, June 30th. Leerink Swann reissued an “outperform” rating and set a $160.00 price objective (up from $150.00) on shares of Celgene Corporation in a report on Friday, July 28th. Argus raised Celgene Corporation from a “hold” rating to a “buy” rating and increased their price objective for the company from $96.93 to $160.00 in a report on Monday, July 31st. Credit Suisse Group set a $148.00 price objective on Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 6th. Finally, Cann reissued a “buy” rating on shares of Celgene Corporation in a report on Wednesday, June 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $147.44.
In other news, insider Rupert Vessey sold 4,785 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the sale, the insider now directly owns 4,004 shares of the company’s stock, valued at approximately $481,200.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Robert J. Hugin sold 175,970 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the completion of the sale, the insider now directly owns 1,033,909 shares in the company, valued at $138,688,553.26. The disclosure for this sale can be found here. Insiders sold a total of 253,761 shares of company stock worth $33,792,445 over the last three months. Insiders own 0.95% of the company’s stock.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.